Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Repligen Corporation Common Stock — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $103.58 (market cap $29.10B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 2.6× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 126 Days and Repligen Corporation Common Stock for 0 Days on average.
| LQD | RGEN | |
|---|---|---|
Market Cap | $29.10B | $11.31B |
Volume | 33,185,388 | 1,216,919 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $194.57 |
52-Week Low | $101.83 | $102.87 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.55, showing minimal daily movement with a slight decline of -0.03%. The ETF faces bearish technical signals across multiple indicators while maintaining regular dividend distributions. Recent news highlights significant short interest growth of 53.1% in September 2026 and unusual options activity, reflecting heightened market uncertainty amid rising bond yields and geopolitical tensions affecting corporate debt markets.
The investment-grade corporate bond ETF faces headwinds from rising Treasury yields and increased borrowing costs for corporations. While the 4.8% yield provides income appeal, the bearish technical outlook and growing short interest suggest near-term pressure. Key risks include further Fed rate hikes and economic slowdown impacting corporate credit quality.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
